Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Radiation therapy before kidney cancer surgery achieved strong one-year survival without major complications, meeting early-stage trial goals.
This phase 2 nonrandomized clinical trial evaluated To evaluate the feasibility, safety, clinical outcomes, and exploratory biomarker effects of neoadjuvant stereotactic ablative radiotherapy (SABR) targeting IVC tumor thrombus before nephrectomy and thrombectomy. The authors report that among 21 evaluable patients, neoadjuvant SABR produced 71,4% one-year recurrence-free survival and met the prespecified phase 2 screening criterion without 90-day perioperative mortality.
What the study was
- Study design
- Phase 2 nonrandomized clinical trial
- Sample size
- 23
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- JAMA oncology
Why it surfaced
8/10: Phase 2 nonrandomized clinical trial with direct relevance to Novel therapeutics: immunotherapy, CAR-T, targeted therapy; scoring remains conservative because triage used the PubMed abstract without full-text review.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.